MA31308B1 - Anticorps antisclerostine. - Google Patents

Anticorps antisclerostine.

Info

Publication number
MA31308B1
MA31308B1 MA32274A MA32274A MA31308B1 MA 31308 B1 MA31308 B1 MA 31308B1 MA 32274 A MA32274 A MA 32274A MA 32274 A MA32274 A MA 32274A MA 31308 B1 MA31308 B1 MA 31308B1
Authority
MA
Morocco
Prior art keywords
antibodies
sclerostine
fight
bone
osteoporosis
Prior art date
Application number
MA32274A
Other languages
Arabic (ar)
English (en)
Inventor
Andrew Ihor Korytko
David Matthew Marquis
Eric Michael Smith
Barbara Anne Swanson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA31308B1 publication Critical patent/MA31308B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des anticorps humanisés et chimériques qui se lient spécifiquement à la sclérostine humaine et sont caractérisés en ce qu'ils présentent une affinité élevée et d'importantes propriétés de neutralisation. Les anticorps de l'invention sont utilisés pour augmenter la masse osseuse, la densité minérale osseuse et la résistance osseuse et pour traiter des troubles variés, par exemple, l'ostéoporose, chez un sujet humain.
MA32274A 2007-03-20 2009-10-12 Anticorps antisclerostine. MA31308B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89581307P 2007-03-20 2007-03-20
PCT/US2008/056527 WO2008115732A2 (fr) 2007-03-20 2008-03-11 Anticorps antisclérostine

Publications (1)

Publication Number Publication Date
MA31308B1 true MA31308B1 (fr) 2010-04-01

Family

ID=39756356

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32274A MA31308B1 (fr) 2007-03-20 2009-10-12 Anticorps antisclerostine.

Country Status (31)

Country Link
US (3) US7744874B2 (fr)
EP (2) EP2131860B1 (fr)
JP (2) JP2010524846A (fr)
KR (1) KR101123487B1 (fr)
CN (1) CN101646457B (fr)
AU (1) AU2008229141B2 (fr)
BR (1) BRPI0809026A2 (fr)
CA (1) CA2682212C (fr)
CO (1) CO6230999A2 (fr)
CR (1) CR11004A (fr)
CY (1) CY1114784T1 (fr)
DK (1) DK2131860T3 (fr)
DO (1) DOP2009000223A (fr)
EA (1) EA018204B1 (fr)
EC (1) ECSP099658A (fr)
ES (1) ES2446293T3 (fr)
HR (1) HRP20140108T1 (fr)
IL (1) IL200437A0 (fr)
MA (1) MA31308B1 (fr)
MX (1) MX2009010051A (fr)
MY (1) MY149129A (fr)
NZ (1) NZ578870A (fr)
PL (1) PL2131860T3 (fr)
PT (1) PT2131860E (fr)
RS (1) RS53157B (fr)
SI (1) SI2131860T1 (fr)
SV (1) SV2009003374A (fr)
TN (1) TN2009000383A1 (fr)
UA (1) UA96474C2 (fr)
WO (1) WO2008115732A2 (fr)
ZA (1) ZA200906345B (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP4813660B2 (ja) 1998-11-27 2011-11-09 ダーウィン ディスカバリー リミテッド 骨鉱化作用を増加するための組成物および方法
US7381409B2 (en) 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
FI3345607T3 (fi) 2006-12-29 2022-11-30 Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia
KR101123487B1 (ko) * 2007-03-20 2012-03-23 일라이 릴리 앤드 캄파니 항?스클레로스틴 항체
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
JP2011506483A (ja) * 2007-12-14 2011-03-03 アムジエン・インコーポレーテツド 抗スクレロスチン抗体を用いた骨折の治療方法
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2275443B1 (fr) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Molécule de liaison à l antigène capable de se lier à deux molécules d antigène ou plus de manière répétée
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
PH12012501991A1 (en) 2010-04-07 2017-07-26 Abbvie Inc Tnf-alpha binding proteins
BR112012026098A2 (pt) 2010-04-16 2016-11-22 Novartis Ag métodos e composições para melhorar a osseointegração de implante.
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
AU2011267869A1 (en) * 2010-06-14 2013-01-10 Vaccinex, Inc. Anti-VEGF antibodies and uses thereof
TWI616204B (zh) 2010-11-05 2018-03-01 諾華公司 Ｉｌ-１７抗體用於製備治療牛皮癬性關節炎之藥物之用途
JP5319651B2 (ja) * 2010-11-18 2013-10-16 日本電信電話株式会社 分析方法
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
CA2858350A1 (fr) 2011-01-14 2013-07-19 The Regents Of The University Of California Anticorps therapeutiques contre la proteine ror-1 et leurs methodes d'utilisation
EP2681242B1 (fr) 2011-03-01 2018-01-24 Amgen Inc. Agents liants bispécifiquement sclérostine et dkk-1
EP2688910B1 (fr) 2011-03-25 2019-05-29 Amgen Inc. Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
RS57877B1 (sr) 2011-04-19 2018-12-31 Amgen Inc Metoda za lečenje osteoporoze
JP2014515759A (ja) 2011-04-29 2014-07-03 ノバルティス アーゲー 扁平上皮がんを治療する方法関連出願
SI2739311T1 (en) * 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
AR088512A1 (es) 2011-10-24 2014-06-18 Abbvie Inc Anticuerpos dirigidos contra el tnf
BR112014009810A2 (pt) 2011-10-24 2017-04-25 Abbvie Inc imunoligantes biespecíficos dirigidos contra tnf e il-17
EP2771360A1 (fr) * 2011-10-24 2014-09-03 AbbVie Inc. Agents de liaison immunologique dirigés contre la sclérostine
EP2797953B1 (fr) 2011-12-28 2020-06-03 Amgen Inc. Méthode de traitement d'une perte osseuse alvéolaire au moyen d'anticorps anti-sclérostine
US9925260B2 (en) 2012-07-05 2018-03-27 Ucb Pharma S.A. Treatment for bone diseases
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US20140065144A1 (en) * 2012-08-30 2014-03-06 National Cheng Kung University Use of il-20 antagonists for promoting bone fracture healing
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (fr) 2013-01-31 2014-08-07 Novartis Ag Procédé de traitement des troubles minéraux et osseux de la maladie rénale chronique en utilisant des antagonistes de la sclérostine
TWI636063B (zh) * 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
WO2014144817A2 (fr) 2013-03-15 2014-09-18 Amgen Inc. Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
WO2014155278A2 (fr) 2013-03-26 2014-10-02 Novartis Ag Méthodes de traitement de maladies auto-immunes à l'aide d'antagonistes de l'il -17
WO2015087187A1 (fr) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anticorps anti-sclérostine
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2016109415A1 (fr) 2014-12-30 2016-07-07 Celgene Corporation Anticorps anti-cd47 et leurs utilisations
WO2016145961A1 (fr) * 2015-03-13 2016-09-22 江苏恒瑞医药股份有限公司 Anticorps anti-sclérostine, fragment de liaison à l'antigène et utilisation médicale associée
KR20250065434A (ko) 2016-03-01 2025-05-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
WO2018031454A1 (fr) 2016-08-08 2018-02-15 Amgen Inc. Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.
KR20190052137A (ko) * 2016-10-28 2019-05-15 일라이 릴리 앤드 캄파니 항-rankl 항체 및 그의 용도
EP3666794A1 (fr) * 2016-11-01 2020-06-17 AnaptysBio, Inc. Anticorps dirigés contre la mort programmée 1 (pd -1)
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
EP3565844B8 (fr) 2017-01-09 2023-04-12 Tesaro, Inc. Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
JP7191833B2 (ja) * 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
US11530240B2 (en) 2017-06-09 2022-12-20 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
CA3069392A1 (fr) 2017-07-27 2019-01-31 Jiangsu Hengrui Medicine Co., Ltd. Composition pharmaceutique d'anticorps sost et utilisations de celle-ci
HRP20260414T1 (hr) 2018-03-30 2026-05-08 Amgen Inc. C-terminalne varijante protutijela
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
EA202190482A1 (ru) 2018-08-10 2021-05-25 Эмджен Инк. Способ получения фармацевтического состава на основе антитела
CA3125033A1 (fr) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps monoclonaux a haute affinite ciblant le glypicane-1 et procedes d'utilisation
MX2022001805A (es) 2019-08-12 2022-06-08 Amgen Inc Formulaciones de anticuerpos anti-esclerostina.
EP4041392A1 (fr) 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Anticorps dirigés contre le récepteur du poliovirus (pvr) et leurs utilisations
AR133302A1 (es) 2023-07-19 2025-09-17 Amgen Inc Métodos de preparación de amortiguador para una formulación de proteína terapéutica
WO2025081137A1 (fr) * 2023-10-12 2025-04-17 The Regents Of The University Of Michigan Agents thérapeutiques ciblant les os
CN119097708B (zh) * 2024-09-04 2025-05-09 中国医学科学院北京协和医院 Dkk1单克隆抗体在制备用于治疗骨质疏松症的药物组合物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
JP4813660B2 (ja) 1998-11-27 2011-11-09 ダーウィン ディスカバリー リミテッド 骨鉱化作用を増加するための組成物および方法
CA2412110A1 (fr) 2000-06-19 2001-12-27 F. Hoffmann-La Roche Ag Polymorphismes genetiques d'osteolevine
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
AU2003283206A1 (en) * 2002-11-27 2004-06-18 Aventis Pharma Deutschland Gmbh A method and a system for establishing a quantity measure for joint destruction
US7381409B2 (en) * 2003-06-16 2008-06-03 Celltech R&D, Inc. Antibodies specific for sclerostin and methods of screening and use therefor
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2006046935A1 (fr) 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc Procedes permettant d'augmenter l'affinite de liaison des regions variables d'anticorps
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2008061013A2 (fr) 2006-11-10 2008-05-22 Amgen Inc. Diagnostic et thérapie basés sur des anticorps
KR101123487B1 (ko) * 2007-03-20 2012-03-23 일라이 릴리 앤드 캄파니 항?스클레로스틴 항체

Also Published As

Publication number Publication date
EA200970874A1 (ru) 2010-02-26
SI2131860T1 (sl) 2014-02-28
ECSP099658A (es) 2009-10-30
BRPI0809026A2 (pt) 2014-09-23
EP2131860A2 (fr) 2009-12-16
HRP20140108T1 (hr) 2014-02-28
CO6230999A2 (es) 2010-12-20
US7988970B2 (en) 2011-08-02
ES2446293T3 (es) 2014-03-07
DOP2009000223A (es) 2009-10-15
UA96474C2 (en) 2011-11-10
MY149129A (en) 2013-07-15
NZ578870A (en) 2012-01-12
CR11004A (es) 2009-11-02
CA2682212C (fr) 2014-05-06
CA2682212A1 (fr) 2008-09-25
WO2008115732A2 (fr) 2008-09-25
MX2009010051A (es) 2009-10-12
JP2010524846A (ja) 2010-07-22
JP5758933B2 (ja) 2015-08-05
RS53157B (sr) 2014-06-30
WO2008115732A3 (fr) 2008-12-11
KR101123487B1 (ko) 2012-03-23
US7744874B2 (en) 2010-06-29
DK2131860T3 (da) 2014-01-13
CN101646457B (zh) 2013-05-01
PT2131860E (pt) 2014-03-04
US20110250205A1 (en) 2011-10-13
ZA200906345B (en) 2010-11-24
EP2664346A1 (fr) 2013-11-20
JP2013151504A (ja) 2013-08-08
EP2131860B1 (fr) 2013-12-18
IL200437A0 (en) 2010-04-29
HK1138790A1 (en) 2010-09-03
CN101646457A (zh) 2010-02-10
US20100221263A1 (en) 2010-09-02
SV2009003374A (es) 2011-01-10
CY1114784T1 (el) 2016-12-14
AU2008229141A1 (en) 2008-09-25
US8257704B2 (en) 2012-09-04
EA018204B1 (ru) 2013-06-28
US20090060924A1 (en) 2009-03-05
PL2131860T3 (pl) 2014-05-30
TN2009000383A1 (en) 2010-12-31
AU2008229141B2 (en) 2013-02-07
KR20090114462A (ko) 2009-11-03

Similar Documents

Publication Publication Date Title
LTPA2022520I1 (fr)
TN2009000383A1 (en) Anti - sclerostin antibodies
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
TW200736274A (en) Immunoglobulins
MX2009001110A (es) Anticuerpos monoclonales anti-il-6 y usos de los mismos.
AR081434A1 (es) Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
TNSN04078A1 (fr) Antibodies to cd40
MY149630A (en) Antibodies against amyloid-beta peptide
GEP20104922B (en) Antibodies to m-csf
WO2008105886A3 (fr) Anticorps spécifiques fcgriib humanisés, et leurs procédés d'utilisation
UA117807C2 (uk) ІМУНОКОН'ЮГАТ, ЩО МІСТИТЬ РЕКОМБІНАНТНЕ АНТИТІЛО ДО РЕЦЕПТОРА ЕПІДЕРМАЛЬНОГО ФАКТОРА РОСТУ ЛЮДИНИ (hEGFR), ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЯКА ЙОГО МІСТИТЬ
MA28982B1 (fr) Anticorps antagonistes de il-17
WO2006125640A3 (fr) Production et profilage d'anticorps therapeutiques entierement humains hucal gold®; propres a la molecule cd38 humaine
UA95478C2 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТ с-Kit
MA32031B1 (fr) Procedes et compositions faisant appel a des polypeptides de fusion klotho-fgf
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
WO2007042309A3 (fr) Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
SI1937721T1 (sl) Anti il protitelesa
MX2010001975A (es) Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso.
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
EA201300418A1 (ru) Антитела к человеческому tweak и варианты их применения
EP3345925A3 (fr) Anticorps humanisés ciblant le domaine ec1 cadhérine-11 et compositions et procédés associés
MA38161A1 (fr) Anticorps anti-bmp-6
SI2791177T1 (en) Molecules that bind thrombin antibodies and their use
WO2009000929A3 (fr) Composition et procédé de traitement de maladie auto-immune